text
stringlengths 0
197k
|
---|
<|newrecord|> nctId: NCT06350188 id: ECM#2024-506 briefTitle: Efficacy of Kinesiotape on Treatment of Nonspecific Cardiac Chest Pain overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-22 date: 2024-06-22 date: 2024-07-22 date: 2024-04-05 date: 2024-04-05 name: Cairo University class: OTHER briefSummary: purpose of the study To investigate the effect of Kinesio-tape on treatment of nonspecific cardiac chest pain conditions: Nonspecific Cardiac Chest Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ACTUAL name: experimental name: traditional measure: PAIN USING VIISUSL ANALOGE SCALE measure: PERSSURE PAIN THRESHOLD measure: SHOULDER RANGE OF MOTION measure: shoulder pain and disability sex: ALL minimumAge: 20 Years maximumAge: 35 Years stdAges: ADULT facility: Huda Badr Abd Elhamed city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
|
<|newrecord|> nctId: NCT06350175 id: 2212697123 briefTitle: Emergency Department Management of Tobacco Use Disorder overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-03 date: 2025-06 date: 2024-04-05 date: 2024-04-16 name: West Virginia University class: OTHER briefSummary: The objective of this study is to determine the effectiveness of ED initiated NRT on tobacco cessation point abstinence rates as reported by patients at 2 weeks and 1 month post randomization, and continued abstinence rates at 3 months compared to standard of care therapy. conditions: Tobacco Use Disorder conditions: Tobacco Use Cessation studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 100 type: ESTIMATED name: Nicotine Replacement Therapy Agent name: West Virginia Quit Line measure: Percentage of Continued Abstinence Rate (2 weeks) measure: Percentage of Continued Abstinence Rate (1 month) measure: Percentage of Continued Abstinence Rate (3 months) measure: Patient Health Questionnaire 2 (Baseline) measure: Patient Health Questionnaire 2 (3 months from baseline) measure: Heaviness of Smoking Index (Baseline) measure: Heaviness of Smoking Index (3 months from baseline) measure: Richmond Test (Baseline) measure: Richmond Test (3 months from baseline) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: West Virginia University city: Morgantown state: West Virginia zip: 26505 country: United States lat: 39.62953 lon: -79.9559 hasResults: False
|
<|newrecord|> nctId: NCT06350162 id: ASTRUM-LC12 briefTitle: Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC overallStatus: RECRUITING date: 2023-10-18 date: 2024-12-31 date: 2025-12-31 date: 2024-04-05 date: 2024-04-05 name: Zhejiang Cancer Hospital class: OTHER briefSummary: This phase II trial compares the effect of adding radiation therapy to the usual maintenance therapy with Serplulimab versus Serplulimab alone in patients who have already received Serplulimab plus chemotherapy for the treatment of extensive stage small cell lung cancer . conditions: Extensive Stage Lung Small Cell Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Serplulimab name: Chest Radiation measure: 1-year Progression-free survival rate measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Duration of response (DOR) measure: Disease control rate (DCR) measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhejiang Cancer Hospital status: RECRUITING city: Hangzhou country: China name: jing Qin role: CONTACT lat: 30.29365 lon: 120.16142 hasResults: False
|
<|newrecord|> nctId: NCT06350149 id: STUDY00004637 id: 1R21DK128731-01A1 type: NIH link: https://reporter.nih.gov/quickSearch/1R21DK128731-01A1 briefTitle: A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis overallStatus: RECRUITING date: 2024-03-22 date: 2025-09 date: 2025-09 date: 2024-04-05 date: 2024-04-05 name: Emory University class: OTHER name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: The goal of this study is to determine the extent to which excess dietary simple sugars serve as a secondary mediating factor in Cystic fibrosis-related diabetes (CFRD) development. The main questions it aims to answer are:
|
* Whether conducting a randomized 2x2 factorial design that evaluates acute postprandial changes in glucose over 2 hours following ingestion of a mixed meal challenge that varies by glycemic index and consumption of a sugar-sweetened beverage is acceptable and feasible.
|
* What are the preliminary changes in postprandial hyperglycemia, islet cell function, and incretin response to a high or low Glycemic Index mixed meal tolerance test (MMTT) with and without Sugar-Sweetened Beverages (SSB) in adolescents and young adults with CF
|
Participants will be randomized to a mixed diet and blood will be drawn before and after the mixed meal challenge. conditions: Cystic Fibrosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: OTHER masking: NONE count: 40 type: ESTIMATED name: Sugar Sweetened Beverages (SSB) name: Hi GI name: Lo GI measure: Recruitment Rate measure: Refusal Rate measure: Investigator Fidelity measure: Participant Fidelity measure: Acceptability measure: Retention Rates measure: Recruitment measure: Change in plasma Cysteine (Cys) measure: Change in plasma Cystine (CySS) measure: Change in plasma Glutathione (GSH) measure: Change in plasma Glutathione Disulfide (GSSG) measure: Change in redox potentials (EhCys/ CySS and EhGSH/GSSG) measure: Insulinogenic index measure: Whole body insulin sensitivity index (WBISI-Matsuda) measure: Disposition Index measure: Change in plasma Eh Cys/CySS measure: Change in incremental glucose AUC measure: Changes in Plasma insulin measure: Changes in Plasma C-peptide measure: Changes in Plasma Glucagon measure: Changes in Plasma Incretins: glucagon-like peptide-1 (GLP-1) measure: Changes in Plasma Incretins: total glucose-dependent insulinotropic polypeptide (GIP) sex: ALL minimumAge: 12 Years maximumAge: 21 Years stdAges: CHILD stdAges: ADULT facility: Center for Advanced Pediatrics: Emory Healthcare status: RECRUITING city: Atlanta state: Georgia zip: 30329 country: United States name: Tanicia Daley, MD role: CONTACT phone: 404-785-5437 email: [email protected] name: Arlene Stecenko, MD role: CONTACT phone: 404-727-1460 email: [email protected] name: Tanicia Daley, MD role: PRINCIPAL_INVESTIGATOR name: Jessica Alvarez, PhD role: SUB_INVESTIGATOR name: Arlene Stecenko, MD role: SUB_INVESTIGATOR lat: 33.749 lon: -84.38798 hasResults: False
|
<|newrecord|> nctId: NCT06350136 id: 2024/05-37 briefTitle: The Effect of Self-Management Support Provided to Hypertension Patients Affected by the Earthquake Via Tele-Nursing on Patients' Treatment Compliance and Self-Care Management overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-12-01 date: 2025-06-01 date: 2024-04-05 date: 2024-04-08 name: Firat University class: OTHER briefSummary: This important research includes a randomized controlled trial evaluating the potential of self-management support provided via telenursing to earthquake-affected hypertension patients to improve patients' treatment adherence and overall self-care management. This study will be carried out at Fırat University Hospital and will cover a wide range of effects on health outcomes in individuals receiving hypertension treatment. The sample selected from hypertension patients, which constitute the population of the research, was based on predetermined power analysis criteria. It has been determined that at least 51 hypertension patients should be included in each of the intervention and control groups, and accordingly, a total of 150 hypertension patients will be included in the study.
|
. The results obtained within this framework may provide guidance in the development and implementation of Turkey's health policies, and may also shed light on strategies for the management of other similar health problems. On the other hand, strengthening the digital health infrastructure and effective management of chronic diseases, which are among the health-related targets of the Development Plan, further emphasize the importance of this research. The success of the self-management model supported by tele-nursing can serve as an example in the integration of digital health technologies into Turkey's healthcare system and be an important step towards achieving strategic goals in this field. conditions: With Tele-Nursing studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 150 type: ESTIMATED name: With Tele-Nursing measure: Hill-Bone Hypertension Treatment Compliance Scale measure: Self-Care Management Scale in Chronic Diseases; measure: Psychological Impact of Earthquake Scale: measure: Earthquake Stress Coping Strategies Scale sex: ALL minimumAge: 55 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06350123 id: D6405C00002 briefTitle: Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease. acronym: MIRO-CKD overallStatus: NOT_YET_RECRUITING date: 2024-05-06 date: 2026-01-13 date: 2026-01-13 date: 2024-04-05 date: 2024-04-05 name: AstraZeneca class: INDUSTRY briefSummary: The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effect of the balcinrenone/dapagliflozin on urinary albumin-to-creatinine ratio (UACR), compared with dapagliflozin in patients with CKD. This is a dose-finding study aiming to identify an optimal dose of balcinrenone/dapagliflozin for a future Phase III study in patients with CKD. conditions: Chronic Kidney Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Multicentre, randomised, double-blind, dose-finding, parallel group, double-dummy primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 300 type: ESTIMATED name: Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg name: Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg name: Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin measure: Relative change in UACR from baseline to Week 12 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site city: San Carlos state: California zip: 94070 country: United States lat: 37.50716 lon: -122.26052 facility: Research Site city: Waterbury state: Connecticut zip: 06708 country: United States lat: 41.55815 lon: -73.0515 facility: Research Site city: Hialeah state: Florida zip: 33012 country: United States lat: 25.8576 lon: -80.27811 facility: Research Site city: Salt Lake City state: Utah zip: 84124 country: United States lat: 40.76078 lon: -111.89105 facility: Research Site city: Norfolk state: Virginia zip: 23504 country: United States lat: 36.84681 lon: -76.28522 facility: Research Site city: Linz zip: 4021 country: Austria lat: 48.30639 lon: 14.28611 facility: Research Site city: St. Pölten zip: 3100 country: Austria lat: 48.2 lon: 15.63333 facility: Research Site city: Vienna zip: A-1090 country: Austria lat: 48.20849 lon: 16.37208 facility: Research Site city: Wels zip: 4600 country: Austria lat: 48.16667 lon: 14.03333 facility: Research Site city: Wien zip: 1030 country: Austria lat: 48.20849 lon: 16.37208 facility: Research Site city: Wien zip: 1130 country: Austria lat: 48.20849 lon: 16.37208 facility: Research Site city: Wien zip: 1190 country: Austria lat: 48.20849 lon: 16.37208 facility: Research Site city: Burgas zip: 8018 country: Bulgaria lat: 42.50606 lon: 27.46781 facility: Research Site city: Dobrich zip: 9300 country: Bulgaria lat: 43.56667 lon: 27.83333 facility: Research Site city: Pleven zip: 5800 country: Bulgaria lat: 43.41667 lon: 24.61667 facility: Research Site city: Plovdiv zip: 4000 country: Bulgaria lat: 42.15 lon: 24.75 facility: Research Site city: Sofia zip: 1680 country: Bulgaria lat: 42.69751 lon: 23.32415 facility: Research Site city: London state: Ontario zip: N6A 5A5 country: Canada lat: 42.98339 lon: -81.23304 facility: Research Site city: Waterloo state: Ontario zip: N2T 0C1 country: Canada lat: 43.4668 lon: -80.51639 facility: Research Site city: Montreal state: Quebec zip: H4J 1C5 country: Canada lat: 45.50884 lon: -73.58781 facility: Research Site city: Quebec zip: G1R 2J6 country: Canada lat: 46.81228 lon: -71.21454 facility: Research Site city: Bari zip: 70124 country: Italy lat: 41.11148 lon: 16.8554 facility: Research Site city: Bologna zip: 40138 country: Italy lat: 44.49381 lon: 11.33875 facility: Research Site city: Genoa zip: 16132 country: Italy lat: 44.40478 lon: 8.94438 facility: Research Site city: Parma zip: 43126 country: Italy lat: 44.79935 lon: 10.32618 facility: Research Site city: Pavia zip: 27100 country: Italy lat: 45.19205 lon: 9.15917 facility: Research Site city: Ipoh zip: 30990 country: Malaysia lat: 4.5841 lon: 101.0829 facility: Research Site city: Kota Bahru zip: 15586 country: Malaysia lat: 6.13328 lon: 102.2386 facility: Research Site city: Kuala Lumpur zip: 59100 country: Malaysia lat: 3.1412 lon: 101.68653 facility: Research Site city: Białystok zip: 15-481 country: Poland lat: 53.13333 lon: 23.16433 facility: Research Site city: Gdańsk zip: 80-546 country: Poland lat: 54.35205 lon: 18.64637 facility: Research Site city: Grodzisk Mazowiecki zip: 05-825 country: Poland lat: 52.10387 lon: 20.6337 facility: Research Site city: Leżajsk zip: 37-300 country: Poland lat: 50.26257 lon: 22.41932 facility: Research Site city: Ruda Śląska zip: 41-709 country: Poland lat: 50.2584 lon: 18.85632 facility: Research Site city: Szczecin zip: 70-111 country: Poland lat: 53.42894 lon: 14.55302 facility: Research Site city: Warszawa zip: 02-798 country: Poland lat: 52.22977 lon: 21.01178 facility: Research Site city: Łódź zip: 92-213 country: Poland lat: 51.75 lon: 19.46667 facility: Research Site city: Żywiec zip: 34-300 country: Poland lat: 49.68529 lon: 19.19243 facility: Research Site city: Barcelona zip: 08036 country: Spain lat: 41.38879 lon: 2.15899 facility: Research Site city: Barcelona zip: 8035 country: Spain lat: 41.38879 lon: 2.15899 facility: Research Site city: Cordoba zip: 14004 country: Spain lat: 37.89155 lon: -4.77275 facility: Research Site city: Palma de Mallorca zip: 07010 country: Spain lat: 39.56939 lon: 2.65024 facility: Research Site city: Sevilla zip: 41013 country: Spain lat: 37.38283 lon: -5.97317 facility: Research Site city: Valencia zip: 46026 country: Spain lat: 39.46975 lon: -0.37739 facility: Research Site city: Kaohsiung zip: 80756 country: Taiwan lat: 22.61626 lon: 120.31333 facility: Research Site city: New Taipei City zip: 220 country: Taiwan lat: 25.01111 lon: 121.44583 facility: Research Site city: Taichung zip: 40201 country: Taiwan lat: 24.1469 lon: 120.6839 facility: Research Site city: Tainan zip: 710 country: Taiwan lat: 22.99083 lon: 120.21333 facility: Research Site city: Taipei City zip: 110 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taipei City zip: 11217 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taipei zip: 10002 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taipei zip: 11490 country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False
|
<|newrecord|> nctId: NCT06350110 id: ESBI202492 briefTitle: Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) acronym: BAH242 overallStatus: NOT_YET_RECRUITING date: 2024-11-10 date: 2025-12-10 date: 2025-12-28 date: 2024-04-05 date: 2024-04-05 name: Essen Biotech class: OTHER briefSummary: This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients suffering from resistant systemic lupus erythematosus can tolerate. conditions: Systemic Lupus Erythematosus conditions: Lupus Nephritis conditions: Autoimmune Diseases conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis conditions: Granulomatous Polyangiitis conditions: Microscopic Polyangiitis conditions: Systemic Sclerosis conditions: Idiopathic Inflammatory Myopathies conditions: Sjogren's Syndrome studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single Group Assignment
|
Patients enrolled in this clinical trial will receive a carefully designed treatment regimen. Prior to the infusion of CD19 and BCMA CAR-T cells, participants will undergo preconditioning chemotherapy. This chemotherapy serves to create an optimal environment for the CAR-T cell therapy to effectively target and eliminate malignant B cells. Following chemotherapy, participants will receive the infusion of CD19 and BCMA CAR-T cells.
|
Monitoring and Follow-up:
|
Following the CAR-T cell infusion, patients will be subjected to rigorous monitoring to assess safety and treatment response. primaryPurpose: TREATMENT masking: NONE maskingDescription: Open-label clinical trials are a category of clinical research where the masking is minimal or nonexistent. In such trials, both the participants and the researchers are fully aware of the treatment assignments, which means participants know the treatment they are receiving, and researchers are aware of each participant's treatment group. count: 75 type: ESTIMATED name: CD19- BCMA CAR-T cells measure: Incidence and severity of dose limiting toxicities (DLTs) following chemotherapy preparative regimen and infusion of CD19/BCMA chimeric antigen receptor (CAR) T cells measure: Rate of successful manufacture and expansion of the CD19/BCMA chimeric antigen receptor (CAR) T cells sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: District one hospital city: Shanghai country: China lat: 31.22222 lon: 121.45806 hasResults: False
|
<|newrecord|> nctId: NCT06350097 id: D516NC00001 briefTitle: Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer acronym: TROPION-Lung14 overallStatus: NOT_YET_RECRUITING date: 2024-05-16 date: 2028-03-21 date: 2032-05-25 date: 2024-04-05 date: 2024-04-10 name: AstraZeneca class: INDUSTRY name: Daiichi Sankyo briefSummary: The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Datopotamab Deruxtecan (i.v. infusion) compared with osimertinib (tablet) monotherapy as a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC.
|
Study details include:
|
1. The study duration will be event-driven, with an estimated duration of approximately 9 years.
|
2. Participants may receive study treatment until disease progression, unacceptable toxicity, or other specific discontinuation criteria are met.
|
3. The visit frequency will be every 3 weeks during the treatment period.
|
Note: Participants on osimertinib treatment (osimertinib only arm or who have discontinued Datopotamab Deruxtecan while are still receiving osimertinib) are required to attend visits to perform assessments every 6 weeks from Cycle 7 until Cycle 17 and then visits every 12 weeks until disease progression, IP discontinuation or primary PFS DCO. Participants who are receiving osimertinib + Datopotamab Deruxtecan are still required to attend visit to perform assessment every 3 weeks (q3w) per SoA. conditions: Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 582 type: ESTIMATED name: Osimertinib name: Datopotamab Deruxtecan measure: To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS by BICR in all randomised participants. measure: To demonstrate the superiority of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of OS in all randomised participants. measure: To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS on CNS metastases in participants with CNS metastases at baseline measure: To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS by investigator in all randomised participants. measure: To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of ORR in all randomised participants with measurable disease at baseline. measure: To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of DoR in all randomised participants with measurable disease at baseline. measure: To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib on the prevention of CNS metastases measure: To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan relative to osimertinib by assessment of PFS2 in all randomised participants measure: To assess the PK of osimertinib and Datopotamab Deruxtecan measure: To investigate the immunogenicity of Datopotamab Deruxtecan measure: To compare the local EGFR mutation test result used for patient selection with the retrospective central cobas® EGFR Mutation Test v2 results from baseline tumour samples measure: To demonstrate the effectiveness of osimertinib in combination with Datopotamab Deruxtecan vs. osimertinib monotherapy based on the cobas® EGFR Mutation Test v2 plasma screening test result for Ex19del or L858R EGFR mutations sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site city: Clayton zip: 3168 country: Australia lat: -37.91667 lon: 145.11667 facility: Research Site city: Kogarah zip: 2217 country: Australia lat: -33.98333 lon: 151.11667 facility: Research Site city: Changchun zip: 130000 country: China lat: 43.88 lon: 125.32278 facility: Research Site city: Chongqing zip: 400030 country: China lat: 29.56278 lon: 106.55278 facility: Research Site city: Jinan zip: 250021 country: China lat: 36.66833 lon: 116.99722 facility: Research Site city: Jinan zip: 250117 country: China lat: 36.66833 lon: 116.99722 facility: Research Site city: Kunming zip: 650118 country: China lat: 25.03889 lon: 102.71833 facility: Research Site city: Linhai zip: 318000 country: China lat: 28.85535 lon: 121.14469 facility: Research Site city: Shanghai zip: 200030 country: China lat: 31.22222 lon: 121.45806 facility: Research Site city: Seoul zip: 06351 country: Korea, Republic of lat: 37.566 lon: 126.9784 facility: Research Site city: Seoul zip: 120-752 country: Korea, Republic of lat: 37.566 lon: 126.9784 facility: Research Site city: Seoul zip: 13620 country: Korea, Republic of lat: 37.566 lon: 126.9784 facility: Research Site city: Taipei City zip: 106 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taipei zip: 10002 country: Taiwan lat: 25.04776 lon: 121.53185 facility: Research Site city: Taoyuan zip: 333 country: Taiwan lat: 24.95233 lon: 121.20193 hasResults: False
|
<|newrecord|> nctId: NCT06350084 id: 2023/381 briefTitle: Effect of Mother's Touch and Nurse's Therapeutic Touch on Pain Level and Crying Time During Heel Blood Collection overallStatus: RECRUITING date: 2023-09-04 date: 2024-07-31 date: 2024-12-31 date: 2024-04-05 date: 2024-04-08 name: Burdur Mehmet Akif Ersoy University class: OTHER briefSummary: This prospective study is planned as a randomized controlled study with the purpose of determining the effect of Mother's Touch and Nurse's Therapeutic Touch on pain levels and crying times by newborns during heel blood collection. conditions: Pain, Acute conditions: Newborn conditions: Crying studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Mother's Touch name: Nurse's Therapeutic Touch measure: NIPS (Neonatal Infant Pain Scale) measure: Crying times measure: Processing time sex: ALL minimumAge: 2 Days maximumAge: 4 Days stdAges: CHILD facility: Burdur Bucak State Hospital status: RECRUITING city: Burdur state: Bucak zip: 15030 country: Turkey name: Selda Ateş Beşirik, PhD. role: CONTACT phone: +905076228189 email: [email protected] name: Selda Ateş Beşirik, PhD. role: PRINCIPAL_INVESTIGATOR name: Emine Geçkil, Prof. role: SUB_INVESTIGATOR lat: 37.72028 lon: 30.29083 hasResults: False
|
<|newrecord|> nctId: NCT06350071 id: 2023/06 briefTitle: Effect of Kangaroo Care and Swaddling Methods on Pain Level and Crying Time During Heel Blood Collection overallStatus: RECRUITING date: 2023-06-19 date: 2024-07-31 date: 2024-12-31 date: 2024-04-05 date: 2024-04-08 name: Burdur Mehmet Akif Ersoy University class: OTHER briefSummary: This prospective study is planned as a randomized controlled study with the purpose of determining the effect of kangaroo care and swaddling methods on pain levels and crying times by newborns during heel blood collection. conditions: Pain, Acute conditions: Newborns conditions: Crying studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Kangaroo Care name: Swaddling measure: NIPS (Neonatal Infant Pain Scale) measure: Crying times measure: Processing time sex: ALL minimumAge: 1 Day maximumAge: 4 Days stdAges: CHILD facility: Burdur Bucak State Hospital status: RECRUITING city: Burdur state: Bucak zip: 15030 country: Turkey name: Selda Ateş Beşirik, PhD. role: CONTACT phone: +905076228189 email: [email protected] name: Selda Ateş Beşirik, PhD. role: PRINCIPAL_INVESTIGATOR name: Emine Geçkil, Prof. role: SUB_INVESTIGATOR lat: 37.72028 lon: 30.29083 hasResults: False
|
<|newrecord|> nctId: NCT06350058 id: 202012005 briefTitle: Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old overallStatus: ACTIVE_NOT_RECRUITING date: 2021-08-03 date: 2023-11-30 date: 2024-10-31 date: 2024-04-05 date: 2024-04-05 name: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd class: INDUSTRY briefSummary: The research objective is to evaluate the safety and tolerability of the inactivated rotavirus vaccine and explore its preliminary immunogenicity. conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 375 type: ACTUAL name: Inactivated rotavirus vaccine (low dose) name: Inactivated rotavirus vaccine (high dose) name: Placebo measure: Incidence rate of AE measure: Incidence rate of SAE sex: ALL minimumAge: 6 Weeks maximumAge: 49 Years stdAges: CHILD stdAges: ADULT facility: Hebei Provincial Center for Disease Control and Prevention city: Shijiangzhuang state: Hebei zip: 050021 country: China lat: 34.61038 lon: 113.58554 hasResults: False
|
<|newrecord|> nctId: NCT06350045 id: supra 11th puncture PCNL briefTitle: High Supracostal Versus Subcostal Puncture in Adult PCNL overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-01 date: 2028-04-01 date: 2028-04-01 date: 2024-04-05 date: 2024-04-05 name: Assiut University class: OTHER briefSummary: as the supra eleventh puncture PCNL is not well investigated in the literature we will conduct that randomised trial in comparison to the subcostal one conditions: Urolithiasis studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: closed envelop whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 162 type: ACTUAL name: PCNL measure: Rate of complications measure: Stone free rate measure: duration of Hospital stay. measure: Operative time sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Assiut University Hospital city: Assiut zip: 11751 country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False
|
<|newrecord|> nctId: NCT06350032 id: TREPaed id: 2023-505082-91-00 type: CTIS briefTitle: Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-11 date: 2028-11 date: 2024-04-05 date: 2024-04-05 name: AOP Orphan Pharmaceuticals AG class: INDUSTRY briefSummary: The goal of this clinical trial is to evaluate safety and tolerability of preservative-free parenteral treprostinil in paediatric patients with PAH (PH Group 1) who are below 18 years of age. The main question it aims to answer is:
|
• if preservative-free parenteral treprostinil is safe and tolerable in the treatment of paediatric PAH in patients who are either treatment-naïve or have been previously treated with commercially available parenteral treprostinil formulations.
|
Participants will receive either subcutaneous (SC) or intravenous (IV) preservative-free treprostinil and will be observed for 5 months (20 weeks ± 1 week). conditions: Pulmonary Arterial Hypertension studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: preservative-free parenteral treprostinil measure: Frequency and seriousness of adverse events and adverse drug reactions measure: Change from baseline in quality of Life (QoL) measure: Change from baseline in 6-minute walk distance (6MWD) measure: Change from baseline in World Health Organization Functional Class (WHO FC) measure: Change from baseline in echocardiography (ECHO) parameters - RA/RV enlargement measure: Change from baseline in echocardiography (ECHO) parameters - RV systolic dysfunction measure: Change from baseline in echocardiography (ECHO) parameters - RV/LV end-systolic ratio (PSAX) measure: Change from baseline in echocardiography (ECHO) parameters - tricuspid annular plane systolic excursion (TAPSE) measure: Change from baseline in echocardiography (ECHO) parameters - S/D ratio (TR jet) measure: Change from baseline in echocardiography (ECHO) parameters - Pulmonary Artery Acceleration Time (PAAT) measure: Change from baseline in echocardiography (ECHO) parameters - pericardial effusion measure: Change from baseline in echocardiography (ECHO) parameters - eccentricity index measure: Change from baseline in echocardiography (ECHO) parameters - acceleration time measure: Change from baseline in plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels measure: Treprostinil plasma concentration sex: ALL maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Medizinische Universität Wien city: Vienna zip: 1090 country: Austria name: Sulaimi Albinni, MD role: PRINCIPAL_INVESTIGATOR lat: 48.20849 lon: 16.37208 facility: Necker-Enfants Malades Hospital, Paris city: Paris zip: 75015 country: France name: Damien Bonnet, Prof role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: Gottsegen National Cardiovascular Center city: Budapest zip: H-1096 country: Hungary name: Laszlo Ablonczy, MD role: PRINCIPAL_INVESTIGATOR lat: 47.49801 lon: 19.03991 facility: Ramón y Cajal University Hospital city: Madrid zip: 28034 country: Spain name: Maria J del Cerro, Prof role: PRINCIPAL_INVESTIGATOR lat: 40.4165 lon: -3.70256 hasResults: False
|
<|newrecord|> nctId: NCT06350019 id: 26379996/91 briefTitle: Vascular Effects of Penil revascularızatıon overallStatus: COMPLETED date: 2013-01-01 date: 2014-08-15 date: 2014-12-25 date: 2024-04-05 date: 2024-04-05 name: Ankara Yildirim Beyazıt University class: OTHER briefSummary: Purpose: The aim of this study is to measure the effects of penile revascularization surgery performed in vascular origin erectile dysfunction (ED) on penile vascular hemodynamic and to determine the importance of vascular parameters in postoperative patient follow-up.
|
Methods: A total of 35 participants who underwent penile revascularization surgery due to vascular ED were included in this study. In the preoperative period and at the 3rd postoperative month, penile color doppler ultrasonography (PCDU) was performed to evaluate cavernosal arteries, dorsal arteries, deep dorsal vein and inferior epigastric artery (IEA) separately. During this evaluation, peak systolic velocity (PSV), end diastolic velocity (EDV), and resistive index (RI) were measured. The International Index of Erectile Function questionnaire (IIEF) was applied to all patients in the preoperative period and at the 3rd postoperative month. The relationship between changes in (IIEF) questionnaire score and penile vascular hemodynamic changes in the postoperative period was evaluated. conditions: Erectile Dysfunction conditions: Erectile Dysfunction Due to Arterial Disease conditions: Erectile Dysfunction Due to Venous Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ACTUAL name: Penile revascularızation measure: The importance of resistive index in evaluating the postoperative success of penile revascularization sex: MALE minimumAge: 23 Years maximumAge: 69 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06350006 id: SHR-A1904-301 briefTitle: SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor overallStatus: RECRUITING date: 2024-05-30 date: 2027-12-30 date: 2028-12-30 date: 2024-04-05 date: 2024-04-26 name: Shanghai Hengrui Pharmaceutical Co., Ltd. class: INDUSTRY briefSummary: This study consists of two research phases:
|
Phase Ib (includes dose escalation phase and efficacy extension phase): To explore the safety, tolerability and initial efficacy of SHR-A1904 in the treatment of CLDN18.2-positive advanced solid tumors, and to determine the recommended dose and recommended population for the Phase III combination study.
|
Phase III: A randomized, double-blind, multicenter clinical study of SHR-1904 combined with chemotherapy and immunotherapy Versus chemotherapy combined with immunotherapy for CLDN18.2-positive advanced solid tumors. conditions: Cldn18.2-positive Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study is a multicenter Phase Ib/III clinical study. Phase Ib consists of two phases, IB-A for dose escalation and IB-B for efficacy extension. The Phase III multi-center, randomized controlled, double-blind study was designed to evaluate the efficacy and safety of SHR-A1904 combined chemotherapy and immunotherapy versus chemotherapy combined immunotherapy in first-line treatment of CLDN18.2-positive solid tumors patients. primaryPurpose: TREATMENT masking: NONE count: 924 type: ESTIMATED name: SHR-A1904; Adebrelimab name: SHR-A1904; CAPOX; Adebrelimab measure: Incidence and severity of AE measure: Dose Limiting Toxicity (DLT) measure: Maximal Tolerable Dose (MTD) measure: Phase III Recommended Dose (RP3D) measure: Progression-free survival (PFS) assessed by blind Independent Center Review (BICR) based on RECIST 1.1 criteria measure: SHR-A1904 toxin binding antibody measure: SHR-A1904 Total antibody measure: Immunogenicity indicators of SHR-A1904: drug resistant antibody (ADA) and neutralizing antibody (NAb) measure: Expression level of CLDN18.2 in tumor tissues measure: Overall survival (OS) measure: Incidence and severity of AE sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen University Cancer Center status: RECRUITING city: Guangzhou state: Guangdong zip: 510060 country: China name: Ruihua Xu role: CONTACT lat: 23.11667 lon: 113.25 hasResults: False
|
<|newrecord|> nctId: NCT06349993 id: pd003 briefTitle: Digital Intervention for Depression and Anxiety in Adolescents overallStatus: RECRUITING date: 2024-04-17 date: 2024-12-30 date: 2025-07-01 date: 2024-04-05 date: 2024-04-22 name: Adai Technology (Beijing) Co., Ltd. class: OTHER briefSummary: The goal of this clinical trial is to evaluate the effectiveness of digital interventions in treating depression and anxiety in adolescents. The main question it aims to answer is: Can digital interventions effectively alleviate symptoms of depression and anxiety in adolescents? The trial will include a comparison group where researchers will compare the effects of the digital intervention to traditional health education methods to assess their relative efficacy.
|
Participants will be asked to engage with the digital intervention platform for a period of two months. conditions: Depression conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Digital Intervention name: Health Education measure: Hamilton Depression Rating Scale measure: Hamilton Anxiety Rating Scale measure: ADHD(attention deficit hyperactivity disorder) Rating Scale-IV measure: PHQ-9 (Patient Health Questionnaire-9) measure: GAD-7 (Generalized Anxiety Disorder-7) sex: ALL minimumAge: 10 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: West China Hospital status: RECRUITING city: Chengdu state: Sichuang country: China name: Liqun Zhang role: CONTACT lat: 30.66667 lon: 104.06667 hasResults: False
|
<|newrecord|> nctId: NCT06349980 id: HLX53-HCC201 briefTitle: A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. overallStatus: NOT_YET_RECRUITING date: 2024-05-10 date: 2027-02-10 date: 2027-02-10 date: 2024-04-05 date: 2024-04-09 name: Shanghai Henlius Biotech class: INDUSTRY briefSummary: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1 Antibody) and HLX04 (a Biosimilar to Bevacizumab) With or Without HLX53 (an Anti-TIGIT Fc Fusion Protein) in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. conditions: Carcinoma, Hepatocellular studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 117 type: ESTIMATED name: HLX53 (1000mg) name: HLX53 (2000mg) name: HLX10 name: HLX04 name: Placebo measure: ORR measure: PFS measure: ORR measure: PFS measure: OS measure: Incidence and severity of adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06349967 id: WCH-2023-1592 briefTitle: Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2027-04-30 date: 2027-05-30 date: 2024-04-05 date: 2024-04-05 name: West China Hospital class: OTHER briefSummary: Currently, standard treatment options for gastric cancer failed to first-line treatment include monotherapy with paclitaxel/irinotecan/docetaxel/albumin paclitaxel, or paclitaxel combined with ramucirumab. However, the efficacy of these regimens is still far from satisfactory. The aim of the study is to evaluate the efficacy and safety of nab-paclitaxel combined with cadonilimab for the second-line treatment of advanced gastric cancer. conditions: Gastric Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 59 type: ESTIMATED name: Nab-paclitaxel Combined With Cadonilimab (AK104) measure: overall response rate (ORR) measure: disease control rate (DCR) measure: overall survival (OS) measure: progression-free survival (PFS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06349954 id: BFHHZS20240064 briefTitle: Effectiveness and Safety of Single-session Endoscopic Stone Extraction overallStatus: RECRUITING date: 2024-04-15 date: 2024-12-01 date: 2024-12-01 date: 2024-04-05 date: 2024-04-18 name: Beijing Friendship Hospital class: OTHER briefSummary: This is a prospective study, including approximately 64 patients with acute cholangitis accompanied with choledocholithiasis at Beijing Friendship Hospital. All patients will be randomly allocate into single-session or two-session endoscopic stone extraction. The investigators assessed the outcomes of single-session and two-session endoscopic stone extraction. conditions: Choledocholithiasis With Acute Cholangitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: All patients will be randomly allocated into single-session group or two-session group. primaryPurpose: TREATMENT masking: NONE count: 64 type: ESTIMATED name: single-session ERCP name: two-session ERCP measure: Success rate of complete stone removal measure: ERCP-related complication rate measure: Length of stay measure: Hospital expenses sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Friendship Hospital status: RECRUITING city: Beijing state: Beijing zip: 100050 country: China name: Wei Jiang role: CONTACT phone: 18663186116 email: [email protected] lat: 39.9075 lon: 116.39723 hasResults: False
|
<|newrecord|> nctId: NCT06349941 id: STU-2023-0745 briefTitle: Telemedicine in Rural Patients With Heart Failure acronym: RURAL-HF overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2024-12-01 date: 2024-12-01 date: 2024-04-05 date: 2024-04-05 name: University of Texas Southwestern Medical Center class: OTHER briefSummary: We propose a pilot trial examining the effectiveness of a mHealth-based home cardiac rehabilitation program using a telemedicine platform for the identification, recruitment, and retention of an underserved rural population with heart failure with reduced ejection fraction.(HFrEF). The goal of the pilot trial will be to demonstrate the feasibility of a telemedicine platform for the recruitment and retention of underserved rural patients in clinical trials. Participants will participate in a cardiac rehabilitation program delivered through a smartphone application called Movn. They will be monitored for 14 weeks. conditions: Heart Failure studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Pilot trial primaryPurpose: OTHER masking: NONE count: 100 type: ESTIMATED name: Movn app measure: Physical activity levels measure: Quality of life using KCCQ score measure: Enrollment rate measure: Loss to follow up sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06349928 id: MASF_Dancers01 briefTitle: "The Show Must go on" : The Experience of Injuries Among Dancers: Fears, Thoughts, and Beliefs. A Qualitative Study overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-10-30 date: 2025-04-01 date: 2024-04-05 date: 2024-04-05 name: University of Siena class: OTHER briefSummary: This qualitative, cross-sectional study aims at describing the experience of Italian dancers with injury.
|
Dancers face a high risk of sustaining one or more injuries during their career (87-94%), which may lead to physical, psychological, and socioeconomic consequences affecting dancer's lives and careers both short and long-term.
|
Dancers report fearing injury and its consequences and believing in the existence of a stigma around injury and injured colleagues; many of them also try to self-manage pain and delay reporting injuries to healthcare professionals, possibly making its outcomes worse.
|
This study will collect data from dancers via focus groups and individual interviews, investigating dancers' experiences, thoughts, and beliefs about injury. Records from the interviews will be transcribed ad verbatim and analyzed using the framework method to synthetize the data and highlight the most meaningful content.
|
Understanding dancers' thoughts and behaviors regarding past or possible future injuries may be beneficial in improving treatment efficacy and designing adequate education and prevention strategies. It may also help raise awareness of dancers' complex and unique needs, and the importance of having accessible, specialized professionals around dance companies and schools. conditions: Injuries conditions: Dancing conditions: Injury;Sports conditions: Stress, Psychological studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 40 type: ESTIMATED name: Focus group or interview measure: Experience and perception of injury amongst dancers measure: Understanding of injury prevention and pain management amongst dancers sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06349915 id: 2023-15217 briefTitle: A Pilot Evaluation of a Digital Peer Support Intervention for Suicidal Adolescents acronym: SWEEP overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-04 date: 2026-04 date: 2024-04-05 date: 2024-04-05 name: Albert Einstein College of Medicine class: OTHER name: American Foundation for Suicide Prevention name: Yeshiva University briefSummary: Suicide risk has increased among youth in underserved communities, where access to mental healthcare is limited. To address this need, the investigator team plans to evaluate the preliminary efficacy of a brief, low-cost, culturally responsive digital intervention for ethnically diverse youth at risk for suicide in The Bronx, NY. In collaboration with community stakeholders, suicide recovery narratives, featuring adolescents' experiences related to recovery from suicidal thoughts will be developed. A smartphone ecological momentary assessment app will be used to evaluate whether a curriculum of these narratives provides anti-suicidal benefits to at-risk adolescents. conditions: Suicide studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The first 6 participants will serve as a brief pilot to validate outcomes and the acceptability of the intervention. The study team may make slight changes to the intervention (e.g., time of day the suicide recovery narratives are administered, or which narratives are presented) before recruiting the remaining 40 participants. primaryPurpose: PREVENTION masking: NONE count: 46 type: ESTIMATED name: Supporting Wellbeing with Everyday Experiences of Peers (SWEEP) measure: Suicidal Thoughts measure: Suicidal Urge Resistance measure: Social Connectedness measure: Optimism measure: Social Support measure: Intervention Acceptability measure: Emotions measure: Treatment Readiness sex: ALL minimumAge: 14 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06349902 id: Pro00077561 briefTitle: Re-link HCV in Substance-Use Telemedicine Program overallStatus: RECRUITING date: 2024-03-12 date: 2024-08-31 date: 2024-12-31 date: 2024-04-05 date: 2024-04-05 name: trueNorth Medical Centres class: OTHER name: Gilead Sciences briefSummary: This is an observational, retrospective \& prospective cohort study. The retrospective element of the study is a chart review to identify people with diagnosed but untreated HCV and re-link them to care. The observational prospective cohort element of the study will examine the HCV linkage to care, treatment initiation, treatment completion \& cure rates of these HCV clients achieved through this chart review and re-linking approach. conditions: Hepatitis C studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 5000 type: ESTIMATED name: Re-Link measure: number of patients identified as having diagnosed but untreated HCV measure: percentage of patients identified as having diagnosed but untreated HCV that are re-linked to HCV care measure: treatment initiation rates measure: treatment completion dates measure: cure rates sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: trueNorth Medical Centre status: RECRUITING city: Toronto state: Ontario zip: M5B 2A5 country: Canada name: Hannah O'Reilly, BSc role: CONTACT phone: 8888783563 phoneExt: 6452 email: [email protected] role: CONTACT phoneExt: Cavacuiti email: [email protected] name: Chris Cavacuiti, BA, MD, MHSc role: PRINCIPAL_INVESTIGATOR lat: 43.70011 lon: -79.4163 hasResults: False
|
<|newrecord|> nctId: NCT06349889 id: MA-NPC-II-004 briefTitle: Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-05-01 date: 2028-05-01 date: 2024-04-05 date: 2024-04-09 name: Sun Yat-sen University class: OTHER name: Nanfang Hospital, Southern Medical University name: West China Hospital briefSummary: This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC). conditions: Nasopharyngeal Carcinoma conditions: Nasopharyngeal Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Adebrelimab measure: Failure-free survival (FFS) measure: Overall survival (OS) measure: Distant metastasis-free survival (DMFS) measure: Locoregional recurrence-free survival (LRRFS) measure: Adverse events (AEs) and serious adverse events (SAEs) measure: Quality of life (QoL) measure: Failure-free survival (FFS) within different subgroups sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanfang Hospital, Southern Medical University city: Guangzhou state: Guangdong zip: 510000 country: China name: Jian Guan, M.D. role: CONTACT lat: 23.11667 lon: 113.25 facility: West China Hospital, Sichuan University city: Chengdu state: Sichuan zip: 610000 country: China name: Lei Liu, M.D. role: CONTACT lat: 30.66667 lon: 104.06667 hasResults: False
|
<|newrecord|> nctId: NCT06349876 id: SUEZ MED - IRB Approval NO: 6 briefTitle: Cholecystectomy in Patients With Silent Common Bile Duct Stones overallStatus: COMPLETED date: 2023-02-15 date: 2023-07-15 date: 2024-01-15 date: 2024-04-05 date: 2024-04-23 name: Suez University class: OTHER briefSummary: Aim of this study is to evaluate the efficacy of performing only cholecystectomy in patients with asymptomatic common bile duct stones without dealing with common bile duct stones conditions: Performing Cholecystectomy in Patients With Chronic Calcular Choleycystits studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 60 type: ACTUAL name: laparoscopic cholecystectomy measure: number of patients developed jaundice post cholecystectomy sex: ALL minimumAge: 25 Years maximumAge: 60 Years stdAges: ADULT facility: Qeft Teatching Hospital city: Qinā country: Egypt lat: 26.16418 lon: 32.72671 facility: Qena Faculty of Medicine city: Qinā country: Egypt lat: 26.16418 lon: 32.72671 facility: Suez Faculty of Medicine city: Suez zip: 43221 country: Egypt lat: 29.97371 lon: 32.52627 hasResults: False
|
<|newrecord|> nctId: NCT06349863 id: W23.225 briefTitle: Dutch CHolEcystitis Snapshot Study acronym: Dutch-CHESS overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-10-31 date: 2025-04-30 date: 2024-04-05 date: 2024-04-11 name: St. Antonius Hospital class: OTHER name: St. Antonius Onderzoeksfonds name: Dutch Snapshot Research Group name: Nederlandse Leverpatientenvereniging briefSummary: Background: Cholecystitis is treated by in various types of hospitals by different specialists, and treatment strategy is influenced by logistical and medical reasons and personal preference. This may significantly impact hospital stay and other outcomes.
|
Purpose: To determine the variation in treatment of cholecystitis in the Netherlands and its impact on outcome.
|
Methods: Nation-wide cohort study of all patients diagnosed and treated for cholecystitis during a 6 month period. The primary outcome will be the proportion of patients with an acute cholecystitis in which the guideline is followed. This group will be compared to those in which the guideline is not followed, focussing on total hospital stay and complications. Secondary aims are to determine: factors related to guideline compliance; the best method of cystic duct closure; the best treatment strategy for a \>7-day existing cholecystitis; factors predictive for concomitant common bile duct stones; strategies following gallbladder drainage. Multivariable analysis and propensity score matching will be used when appropriate for the etiological study aims. The TRIPOD guideline for prediction modelling will be used for the predictive study aims. Hospitals will receive their own results, set out against the national average and best practices, thereafter subsequent changes in hospital practice will be recorded.
|
Conclusion: This study will determine the variation in treatment of cholecystitis in the Netherlands and its impact on clinical outcome. Its results will serve as an important incentive to create optimal, uniform cholecystitis treatment in the Netherlands. conditions: Cholecystitis conditions: Cholecystitis; Gallstone conditions: Cholecystitis; Choledocholithiasis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 3000 type: ESTIMATED measure: Total hospital stay sex: ALL minimumAge: 18 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06349850 id: Soh-Med-24-03-06MS briefTitle: Predictive Value of Serum Uric Acid to High Density Lipoprotein Cholesterol Ratio for Diabetic Kidney Injury in Type 2 Diabetes overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-09 date: 2024-09 date: 2024-04-05 date: 2024-04-05 name: Sohag University class: OTHER briefSummary: An prospective observetional study to asses the predictive value of serum uric acid to high density lipoprotein cholesterol ratio for diabetic kidney injury in type 2 diabetes conditions: Diabetic Kidney Disease studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: serum uric acid level to plasma HDL-c level ratio (UHR) measure: Uric acid to HDL-c ratio (UHR) sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06349837 id: ECLIPSE-02 briefTitle: Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-03-31 date: 2026-03-31 date: 2024-04-05 date: 2024-04-05 name: Sichuan University class: OTHER briefSummary: This is a 3+3 dose escalation phase I study which aims to evaluate the safety and tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative Radiotherapy (SBRT) and Tislelizumab in Patients with bulky tumors who have failed standard therapy. At least 9 participants will be enrolled in this study. conditions: Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 9 type: ESTIMATED name: Tislelizumab name: Low Dose Radiotherapy name: Stereotactic Ablative Radiotherapy measure: Dose Limiting Toxicities measure: Objective Response Rate (ORR) measure: Progression Free Survival (PFS) measure: Overall Survival (OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06349824 id: 004AEstb/EC/01/2022 briefTitle: Dextrose, Steroid, PRP: Choosing the Right Injection for CRS Relief; a RCT overallStatus: COMPLETED date: 2023-10-10 date: 2024-03-30 date: 2024-03-30 date: 2024-04-05 date: 2024-04-05 name: Sheikh Zayed Medical College class: OTHER_GOV briefSummary: USG guided injections to relieve carpal tunnel syndrome with dextrose water or steroid or PRP conditions: Carpal Tunnel Syndrome studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ACTUAL name: injection Dextrose water name: USG machine measure: VAS sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sheikh Zayed Medical College city: Rahim yar khan state: Punjab zip: 64200 country: Pakistan lat: 28.41987 lon: 70.30345 hasResults: False
|
<|newrecord|> nctId: NCT06349811 id: BL-M05D1-101 briefTitle: A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2026-05 date: 2024-04-05 date: 2024-04-09 name: Sichuan Baili Pharmaceutical Co., Ltd. class: INDUSTRY name: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. briefSummary: This study is an open-label, multicenter, dose-escalation, and extended-enrollment nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M05D1 in patients with locally advanced or metastatic solid tumors. conditions: Locally Advanced or Metastatic Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: BL-M05D1 measure: Phase Ia: Dose limiting toxicity (DLT) measure: Phase Ia: Maximum tolerated dose (MTD) measure: Phase Ib: Recommended Phase II Dose (RP2D) measure: Treatment-Emergent Adverse Event (TEAE) measure: Cmax measure: Tmax measure: T1/2 measure: AUC0-t measure: CL (Clearance) measure: Ctrough measure: ADA (anti-drug antibody) measure: Phase Ib: Objective Response Rate (ORR) measure: Phase Ib: Disease Control Rate (DCR) measure: Phase Ib: Duration of Response (DOR) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Cancer Hospital city: Beijing state: Beijing country: China name: Lin Shen role: CONTACT lat: 39.9075 lon: 116.39723 hasResults: False
|
<|newrecord|> nctId: NCT06349798 id: DR200177 briefTitle: Early and Late Effects of Nefopam in Multimodal Analgesia After Total Hip Arthroplasty (NEFARTHRO) acronym: NEFARTHRO overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-09 date: 2027-04 date: 2024-04-05 date: 2024-04-05 name: University Hospital, Tours class: OTHER briefSummary: NEFARTHRO is a multicentric randomized controlled trial comparing the effects of discontinuous infusions of nefopam (bolus) versus continuous infusion of intravenous nefopam (via an infusion pump) versus placebo on the opioid-request during the first 24 hours following a Total Hip arthroplasty, as part of multimodal analgesia including at least paracetamol and a Non-Steroidal Anti-Inflammatory Drug (NSAID).
|
The primary endpoint is cumulative morphine consumption for the first postoperative 24 hours, expressed in mg of iv equivalent morphine, including titration in the Post Anesthesia Care Unit (PACU).
|
Patients will be followed during 6 months. conditions: Total Hip Arthroplasty studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Multicenter, double-blind, randomized controlled trial in 3 parallel groups (placebo group, nefopam bolus group and nefopam Continuous Intra-Venous Infusion CIVI group). primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Patient, investigator and outcome assessor will be blind., A nurse anesthetist who will not be involved in the follow up of the patient will receive the kit and prepare the syringes. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 546 type: ESTIMATED name: Nefopam name: Nefopam name: NaCl 0.9% measure: Cumulative morphine consumption from the end of surgery (Day 0 - Hour 0) to the first 24 hours after surgery, expressed in mg of intravenous morphine (including titration in the Post-Anesthesia care Unit PACU). measure: Maximum self-assessed pain using the Numeric Rating Scale ranging from 0 (no pain) to 10 (maximum pain) at rest in the PACU, at rest and on walking between PACU discharge and Hour 24, at Hour 24, and at hospital discharge. measure: Time to return to walking. measure: Time to leave room. measure: Time to climb stairs. measure: Length of stay. measure: Time to abandon canes/crutches. measure: Opioid analgesic consumption between days 1 and 5 or at hospital discharge measure: Chronic pain at 6 months (at rest and walking) using a standardized phone questionnaire. measure: Neuropathic pain score (DN2)The DN2 is a simplified version of the DN4, with 7 items: burning, painful cold, electric shocks, tingling, pins and needles, numbness, itching (scored 0=absent, 1=present). measure: Incidence of all serious AEs during patient follow-up and non-serious AEs. measure: Incidence of patients with morphine side effects measure: Financial impact of spreading the recommended strategy following the results of the clinical study, estimated per year and over a 5-year period, from the point of view of the French Health Insurance and from the hospital perspective. sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Anaesthesia - Intensive care city: Angers zip: 49933 country: France name: Emmanuel RINEAU, MD role: CONTACT phone: 02 41 35 39 51 phoneExt: +33 email: [email protected] name: Emmanuel RINEAU, MD role: PRINCIPAL_INVESTIGATOR lat: 47.46667 lon: -0.55 facility: Anaesthesia - Intensive care city: Blois zip: 41016 country: France name: Raphaël DARMON, MD role: CONTACT phone: 02 54 55 66 33 phoneExt: +33 email: [email protected] name: Raphaël DARMON, MD role: PRINCIPAL_INVESTIGATOR lat: 47.58333 lon: 1.33333 facility: Anaesthesia - Intensive care city: Chartres zip: 28018 country: France name: Elias CHADDOUK, MD role: CONTACT phone: 02 37 30 30 30 phoneExt: +33 email: [email protected] name: Elias CHADDOUK, MD role: PRINCIPAL_INVESTIGATOR lat: 48.44685 lon: 1.48925 facility: Anaesthesia - Intensive care city: Nantes zip: 44000 country: France name: Raphaël CINOTTI, MD role: CONTACT phone: 02 53 48 22 30 phoneExt: +33 email: [email protected] name: Raphaël CINOTTI, MD role: PRINCIPAL_INVESTIGATOR lat: 47.21725 lon: -1.55336 facility: Anaesthesia - Intensive care city: Orléans zip: 45067 country: France name: Léa PARCOT, MD role: CONTACT phone: 02 38 22 97 17 phoneExt: +33 email: [email protected] name: Léa PARCOT, MD role: PRINCIPAL_INVESTIGATOR lat: 47.90289 lon: 1.90389 facility: Anaesthesia - Intensive care city: Poitiers zip: 86021 country: France name: Denis FRASCA, MD role: CONTACT phone: 05 49 44 38 95 phoneExt: +33 email: [email protected] name: Denis FRASCA, MD role: PRINCIPAL_INVESTIGATOR lat: 46.58333 lon: 0.33333 facility: Anesthesia - intensive care city: Tours zip: 37044 country: France name: Francis REMERAND, MD role: CONTACT phone: 02 47 47 84 80 phoneExt: +33 email: [email protected] name: Francis REMERAND, MD role: PRINCIPAL_INVESTIGATOR lat: 47.38333 lon: 0.68333 hasResults: False
|
<|newrecord|> nctId: NCT06349785 id: P.T.REC/012/003858 briefTitle: Manual Hyperinflation and Physical Therapy Program on Lung Recruitment Mechanically Ventilated Pediatric Patients acronym: MHI overallStatus: COMPLETED date: 2023-12-20 date: 2024-03-01 date: 2024-03-29 date: 2024-04-05 date: 2024-04-05 name: New Ismailia National University class: OTHER briefSummary: The purpose of this study is to investigate the immediate combined effects of Manual Hyperinflation and standard Physical therapy program on lung recruitment and secretion mass in mechanically ventilated pediatric patients aged between 10-15 years 'old conditions: Mechanical Ventilation Complication conditions: Physical Disability studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized controlled trial primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: using sealed envelopes, whoMasked: PARTICIPANT count: 32 type: ACTUAL name: rehabilitation of mechanically ventilated patients name: supportive care measure: change the respiratory functions measure: change the respiratory mechanics measure: change the bronchospasm measure: change the amount of ventilation measure: decreasing the amount of secretions measure: weaning from mechanical ventilator sex: ALL minimumAge: 10 Years maximumAge: 15 Years stdAges: CHILD facility: College of Medicine city: Ismailia zip: 41522 country: Egypt lat: 30.60427 lon: 32.27225 hasResults: False
|
<|newrecord|> nctId: NCT06349772 id: FY2024-203 briefTitle: Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2025-04-01 date: 2024-04-05 date: 2024-04-08 name: Texas Tech University Health Sciences Center class: OTHER briefSummary: The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two extended local anesthesia strategies currently approved by FDA and on the market for post-surgical pain control. The investigators plan on randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively both in the hospital and at home. The investigators will measure the outcome of two drugs, Zynrelief, and Exparel on postoperative pain score -using the NRS pin score up to 72 hours after surgery. The total opioid use will be recorded in forms that will be used to measure pain score and total opioid use and will be collected to the Excel sheet. The cost of the drug will be calculated for internal use for Hospital purpose only. conditions: Post Operative Pain studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 130 type: ESTIMATED name: Zynrelef name: Exparel measure: postoperative pain score measure: Total postoperative opioid use measure: Proportion of total rescue medication use sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06349759 id: OPI-NYXDLD-302 briefTitle: Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances acronym: LYNX-2 overallStatus: RECRUITING date: 2024-04-01 date: 2025-09 date: 2025-11 date: 2024-04-05 date: 2024-04-08 name: Ocuphire Pharma, Inc. class: INDUSTRY name: Viatris Inc. briefSummary: Safety and efficacy of 0.75% Phentolamine Ophthalmic Solution to improve mesopic low contrast visual acuity in subjects with post-refractive surgery visual disturbances. conditions: Mesopic Vision conditions: Night Vision Loss studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 200 type: ESTIMATED name: phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist name: Placebo measure: Percent of subjects with an increase of at least 15 ETDRS letters read (≥ 3 lines) in the study eye in mLCVA compared to Baseline (Day 1 pre-dose) at Day 15 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: United States, California status: RECRUITING city: Newport Beach state: California zip: 92663 country: United States lat: 33.61891 lon: -117.92895 facility: United States, North Carolina status: RECRUITING city: Garner state: North Carolina zip: 27529 country: United States lat: 35.71126 lon: -78.61417 facility: United States, Rhode Island status: RECRUITING city: Warwick state: Rhode Island zip: 02888 country: United States lat: 41.7001 lon: -71.41617 hasResults: False
|
<|newrecord|> nctId: NCT06349746 id: collage of physical therapy briefTitle: Cervical Unilateral Antero-posterior Mobilization and Thoracic Central Postro-anterior Mobilization in Treatment of Shoulder Impingement Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-05 date: 2024-06 date: 2024-04-05 date: 2024-04-05 name: Egyptian Chinese University class: OTHER name: Benha University briefSummary: Shoulder impingement syndrome (SIS) is a complex, multi-factorial problem that is treated with a variety of different conservative options. The conservative option that has shown effectiveness is manual therapy of the cervical and thoracic spine conditions: Shoulder Impingement studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: this study will be conducted to compare one group receiving selected therapeutic exercises and other group recieve cervical and thoracic mobilization added to selected therapeutic exercise Program on pain intensity, Pain-free shoulder flexion and scaption active ROM, muscle strength of external rotator and abductors, shoulder functional status in patients with Shoulder Impingement Syndrome. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: patients and outcomes assessor will be masked about the grouping of the study whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: therapeutic exercises name: mobilization exercise measure: pain intensity measure: shoulder flexion and abduction range of motion measure: muscle strength sex: ALL minimumAge: 20 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06349733 id: MR-37-23-008382 briefTitle: Effectiveness of Botulinum Toxin A in Preventing Scar Formation and Initial Exploration of "Optimal Concentration" overallStatus: ACTIVE_NOT_RECRUITING date: 2023-03-23 date: 2023-11-10 date: 2024-04-10 date: 2024-04-05 date: 2024-04-05 name: Qilu Hospital of Shandong University class: OTHER briefSummary: Each year, millions of burn, trauma, or surgical patients worldwide suffer from scarring that severely affects their quality of life and social functioning. In order to prevent and treat diseases related to abnormal scar hyperplasia, clinicians and researchers have adopted various methods, such as scar grinding, surgical resection, drug injection in scar tissue, cryotherapy, laser and so on. However, these methods can not effectively inhibit the abnormal proliferation of scars and improve the adverse effects of existing scars on patients. To date, there is no accepted gold standard for the effective treatment and improvement of abnormal scar tissue. conditions: Scar studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 50 type: ACTUAL name: Botulinum toxin type A measure: The modified Stony Brook Scar Evaluation Scale measure: Patient satisfaction sex: ALL minimumAge: 12 Years maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Qilu Hospital of Shandong University Dezhou Hospital city: Dezhou state: Shandong zip: 253000 country: China lat: 37.45127 lon: 116.31046 hasResults: False
|
<|newrecord|> nctId: NCT06349720 id: KF-2023-355 briefTitle: Investigating Long-term Health Effects and Complications in COVID-19 Recoveries overallStatus: RECRUITING date: 2023-06-07 date: 2024-06-07 date: 2024-06-07 date: 2024-04-05 date: 2024-04-05 name: Zhaohui Tong class: OTHER briefSummary: Clarify the incidence of functional impairments in cured COVID-19 patients and identify influencing factors. Build a multi-omics database for COVID-19 patients in the recovery period to elucidate the biological biomarkers and targets associated with functional impairments. Comprehensive exploration of the long-term prognosis, complications, sequelae, and risk factors of COVID-19 patients after Omicron infection, as well as their immune characteristics. Compare the impact of different strains of the COVID-19 virus on prognosis and immune response. Develop comprehensive rehabilitation intervention strategies for COVID-19 patients with functional impairments and evaluate the impact of different intervention methods on their prognosis. Based on clinical data, multi-omics data, and precise rehabilitation assessment data, construct predictive models for prognosis and rehabilitation effectiveness in COVID-19, providing scientific evidence for the implementation of effective COVID-19 rehabilitation measures. conditions: COVID-19 Patients studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 17000 type: ESTIMATED name: respiratory rehabilitation measure: Immunological characteristics associated with functional impairments in COVID-19 convalescent patients measure: Changes in laboratory examination indicators measure: High-resolution CT of the chest measure: Pulmonary function test measure: Multi-omics changes and characteristics associated with functional impairments in COVID-19 convalescent patients measure: Inflammatory factors related to body dysfunction in COVID-19 rehabilitation patients measure: Regular rehabilitation assessment following respiratory rehabilitation intervention in COVID-19 patients sex: ALL minimumAge: 18 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Institute of Respiratory Medicine status: RECRUITING city: Beijing state: Beijing zip: 100027 country: China name: Zhaohui Tong, Dr role: CONTACT phone: +86 010 8523 1000 email: [email protected] lat: 39.9075 lon: 116.39723 hasResults: False
|
<|newrecord|> nctId: NCT06349707 id: 2023PI112 briefTitle: Multiplex PCR for Severe Respiratory Infections During the COVID-19 Pandemic acronym: VirCoV+ overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-05 date: 2024-06 date: 2024-04-05 date: 2024-04-05 name: Central Hospital, Nancy, France class: OTHER briefSummary: The hypothesis was that a retrospective investigation of the molecular virological tests in a University hospital could be informative, with the aim to identify non-COVID-19 respiratory viruses during the circulation of SARS-CoV-2, according to systematic population data for public health knowledge. conditions: Viral Pneumonia studyType: OBSERVATIONAL observationalModel: ECOLOGIC_OR_COMMUNITY timePerspective: RETROSPECTIVE count: 18 type: ESTIMATED name: other: Observational measure: Occurrence of positive viral PCR assays (not COVID-19) from hospitalizations for respiratory infections. measure: Real-life features of patients in Intensive care (from the whole population - Outcome 1) with positive viral PCR during infectious pneumonia. sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Schvoerer city: Vandoeuvre Les Nancy zip: 54511 country: France lat: 48.65 lon: 6.18333 hasResults: False
|
<|newrecord|> nctId: NCT06349694 id: PamukkaleU.ftr-NYıldız-001 briefTitle: Comparison of the Efficacy of Transcutaneos Nerve Stimulations in Women With Idiopathic Overactive Bladder overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2025-01-31 date: 2025-02-28 date: 2024-04-05 date: 2024-04-05 name: Pamukkale University class: OTHER briefSummary: Our study is the first prospective randomized controlled trial that compares the effectiveness of transcutaneous medial plantar nerve stimulation (T-MPNS) and transcutaneous tibial nerve stimulation (TTNS) added to bladder training (BT) in women with idiopathic overactive bladder (OAB). İn this study, we aimed to assess the efficacy of T-MPNS and TTNS added to BT on quality of life (QoL) and clinical parameters asssociated with idiopathic OAB. In addition, preparation time for stimulation, treatment satisfaction and discomfort levels of the patients were evaluated.
|
The main questions we aim to answer are:
|
Is T-MPNS as effective as TTNS in the treatment of idiopathic OAB? For this purpose, we planned to compare transcutaneous applications of the tibial and plantar medial nerve in women with idiopathic OAB. 60 women with OAB will be randomized to 3 groups by using random number generator: BT program alone to Group 1 (n=20), BT plus T-MPNS to Group 2 (n=20), BT plus TTNS to Group 3 (n=20) will be applied. conditions: Urinary Bladder, Overactive studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Transcutaneous MPN stimulation (T-MPNS) name: Transcutaneous tibial nerve stimulation (TTNS) name: BT (Control group) measure: Improvement in incontinence episodes (positive response rate) measure: The severity of incontinence measure: Symptom severity measure: Frequency of voiding, nocturia, number of pads measure: Quality of life (IIQ7) measure: The Hospital Anxiety and Depression Scale (HAD) measure: FSFI measure: Cure-improvement rates measure: Treatment satisfaction sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pamukkale University city: Denizli country: Turkey lat: 37.77417 lon: 29.0875 hasResults: False
|
<|newrecord|> nctId: NCT06349681 id: CONOXBird briefTitle: Describe Relations Between qCON and qNOX Indicies During Propofol-Remifentanil General Anesthesia overallStatus: RECRUITING date: 2024-04-01 date: 2024-09-01 date: 2024-10-01 date: 2024-04-05 date: 2024-04-25 name: University of Padova class: OTHER briefSummary: CONOX is a neuromonitoring EEG- device for sedation (qCON) and analgesia (qNOX) monitoring during general anesthesia.
|
It is unknown on how the indicies can differentiate themselves so aim of this study is to determine the relationship bewtween the 2 indicies. conditions: Anesthesia Brain Monitoring studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 14 type: ESTIMATED measure: Correlation between qCON and qNOX measure: Correlation between qCON and concentrations of Propofol(CeP) measure: Correlation between qNOX and concentrations of Remifentanil (CeR) sex: FEMALE minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Treviso Regional Hospital status: RECRUITING city: Treviso state: TV zip: 31100 country: Italy name: Federico Linassi role: CONTACT email: [email protected] lat: 45.66673 lon: 12.2416 hasResults: False
|
<|newrecord|> nctId: NCT06349668 id: 2023-505941-21-00 briefTitle: Spinal Morphine or Intravenous Lidocaine in Robot-assisted Upper Urologic Surgery acronym: SMILe overallStatus: RECRUITING date: 2024-04-09 date: 2026-10-01 date: 2026-12-01 date: 2024-04-05 date: 2024-04-11 name: Hans Bahlmann class: OTHER name: Linkoeping University briefSummary: The goal of this clinical trial is to learn whether the addition of spinal analgesia leads to superior recovery in patients undergoing robotic-assisted laparoscopic upper urinary tract surgery under general anesthesia. The main questions it aims to answer are:
|
* Is the decrease in wellbeing as quantified by the patient-centered outcome scale "Quality of Recovery 15" (QoR-15), from baseline to the first day after surgery (POD 1), at least 8.0 points less in patients receiving spinal analgesia in addition to general anesthesia?
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.